Close Menu

Somalogic

Using two-sample Mendelian randomization and colocalization analysis along with plasma proteomics, they identified 111 potential protein-disease links.

SomaLogic will analyze more than 40,000 samples, including from Amgen clinical trials, using its SomaScan platform, which measures up to 5,000 proteins.

High throughput and deep coverage have allowed firms like Olink and Somalogic to make inroads, especially among researchers working outside proteomics.

Highlights included mass spec-focused developments like data-independent acquisition and ion mobility along with platforms including Thermo Fisher's Q Exactive.

The researchers used the SomaScan platform to measure 5,000 plasma proteins across 17,000 patients and develop protein profiles correlated to 11 health conditions.

Under the 10-year deal, SomaLogic will analyze at least 250,000 clinical samples to support Novartis' drug development work and its own test development.

While the approach lost some of its luster after failing to deliver on early hype, technological improvements are revitalizing interest among researchers.

Agilent has agreed to provide customized high-fidelity oligo microarrays for the nucleic acid detection step in SomaLogic's Somascan assay.

Somalogic will use its SomaScan platform to analyze at least 15,000 clinical samples from Janssen to identify protein biomarkers for various diseases.

Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.